November Is National Diabetes Month: A Father’s Search for a Cure Puts Mesogen’s Cell Therapy Research in the Spotlight

Physician-inventor Dr. Michael Riddle Jr. highlights personalized cell therapy’s potential to restore insulin production and invites investors to explore Mesogen’s vision for regenerative medicine

THE WOODLANDS, Texas — For Dr. Michael Riddle Jr., the pursuit of a cure for Type 1 diabetes begins at home. His son lives with the disease. This November, National Diabetes Month, the physician, engineer and entrepreneur is bringing attention to Mesogen’s mission: developing personalized cell therapies that could help restore the biological functions disease takes away.

As CEO and Chief Scientific Officer of Mesogen, Dr. Riddle is working toward a future in which patients’ own cells become the foundation for treatment. His son’s experience gives that work a deeply personal purpose, turning the search for a lasting solution into both a scientific ambition and a father’s commitment.

Working toward restoring insulin production

Mesogen is developing insulin-producing beta-like cell grafts from a patient’s own cells, an approach designed to help restore the body’s ability to produce insulin.

For Dr. Riddle, this work represents a potential path to a cure for Type 1 diabetes, a mission inspired by his son’s life with the disease. His goal is to replace lost insulin-producing function with personalized living tissue, potentially reducing or eliminating dependence on externally administered insulin.

By using cells derived from each patient, Mesogen aims to avoid the need for long-term anti-rejection medication. The company’s research focuses on translating that scientific promise into a durable treatment, with the ultimate ambition of making lasting insulin independence possible.

An inventor’s journey, featured in Inc. and Popular Mechanics

Dr. Riddle’s work recently drew coverage in Inc. and Popular Mechanics, which chronicled how he fashioned a large lung bioreactor using a $20 fish tank while studying medicine at the University of Texas Medical Branch.

That resourceful invention helped advance research into growing engineered lungs outside the body. His bioreactor design was subsequently sold to Harvard Apparatus, connecting a medical student’s unconventional idea with the wider regenerative medicine research community.

A vision beyond diabetes

Mesogen’s ambitions also extend to retinal pigment epithelium cell patches for macular degeneration. Together, its diabetes and retinal programs reflect a broader vision: using a person’s own cells to replace damaged tissue and recover lost function.

For Dr. Riddle, these programs build on a career spanning lung, kidney, heart and heart valve regenerative medicine research. The long-term opportunity is to explore how personalized tissue engineering might address additional diseases where damaged or lost cells drive disability.

Investor and strategic partner meetings

This National Diabetes Month, Mesogen invites prospective investors and strategic partners to meet with Dr. Riddle to discuss its development programs, scientific approach and long-term commercialization vision.

To request a meeting, contact contact@mesogen.com or call 832-247-3218. Learn more at mesogen.com.